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Previously, the only clinical consequence of HIV vi-
ral replication was thought to be a declining CD4 cell 
count, and development of resistance if on antiretroviral 
therapy (ART). Several recent studies have dramatically 
changed that understanding. Continuing viral replica-
tion seems to play a role in a bewildering array of ill-
nesses not usually associated with HIV, including a di-
verse number of cancers, as well as chronic liver, kidney 
and cardiovascular disease. 
Viraemia used to be regarded as a necessary evil. In the 
1990s, an undetectable viral load was more the excep-
tion than the norm in developed countries, owing to 
drug toxicity and poor adherence. Increasing evidence 
that persistent viraemia is linked to the host of long-
term consequences described above has changed the 
game. In 2009, a detectable viral load should probably be 
regarded as the notional equivalent of active cigarette 
smoking, and tackled with the same vigour.
Luckily, the pharmaceutical industry has rapidly brought 
several new and exciting but expensive ARV agents to 
the marketplace, providing new options for those with 
the money to pay for them.
In developing countries, there are complex drug interac-
tions between rifampicin and the azoles, which patients 
are often on at the time of ART. Side-effects to stavu-
dine and nevirapine remain distressingly common. In 
addition, new insights on resistance, especially subtype 
C, which may compromise future options around teno-
fovir, have begun appearing.  A recent developing world 
study demonstrating increased rates of NNRTI-based 
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The rise of novel antiretrovirals (ARVs) has introduced a new evolutionary phase in HIV care. In developed coun-
tries, the 1980s and early 1990s were characterised by palliative care and opportunistic infection prophylaxis; the 
late 1990s by an attempt to use a limited and toxic antiretroviral arsenal effectively while cycling through high 
levels of resistance; and finally, the first half of this decade by working out the easiest-to-take regimens, using the 
steadily rising number of safer drugs. At present, there are 8 nucleoside analogues (NRTIs), 3 non-nucleoside ana-
logues (NNRTIs), 10 protease inhibitors (PIs), and one each of the fusion, entry and integrase inhibitors to choose 
from, along with a new drug pipeline that targets both existing and new targets in the viral replicative cycle. The 
choice may seem quite vast, but the reality is that many of these drugs cannot be used simultaneously or in pa-
tients with extensive drug resistance. In addition, some drugs have unacceptable toxicities and are not favoured 
in current treatment regimens. 
The newcomers take on the establishment: will cost allow 
widespread use?
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regimen failure after single-dose nevirapine for preven-
tion of mother-to-child transmission emphasised the 
clinical consequences of the low resistance threshold of 
these drugs. Drug resistance to any infectious disease in 
the presence of antimicrobial pressure is near inevitable, 
and needs to be factored into any treatment algorithm. 
In the case of HIV, the stakes are higher when cross-re-
sistance is considered, as the treatment is lifelong, and 
treatment options in poorer areas are limited. Combina-
tions of genotyping and phenotyping resistance testing 
remain prohibitively expensive for the developing world. 
Drugs that may overcome both primary and secondary 
resistance therefore become more important in both the 
developed and developing world scenario.  
Essentially, Southern Africa needs safer, more effective 
and cheaper ART options.
Enter the classes of drugs with science-fiction names 
– the CCR-5 blockers, fusion inhibitors, integrase inhibi-
tors, maturation inhibitors – as well as safer and more 
potent versions of existing classes, with chest-thump-
ing names for trials, such as MOTIVATE, RESIST, TITAN 
and BENCHMRK. One ART advertisement even shows an 
HIV ‘meteor’ heading for a cellular planet, protected by 
a ring of the drug.  Immediate results with these new 
therapeutics have left new-drug junkies open-mouthed, 
as patients with detectable viral loads for decades after 
being on every conceivable ART regimen are consigned 
to ‘undetectable’.
INtEGRASE INHIBItORS
These drugs block integrase, which mediates the insertion 
of HIV DNA into the genome. The integration process is 
complex, and there is interest in directing new drugs at 
several steps in the integration process, which includes 
the assembly of a ‘pre-integration complex’, processing 
with subsequent strand transfer, and the final step of 
assembling a viable piece of double-stranded DNA. 
The first drug to hit the market in this class is raltegra-
vir (Isentress; Merck Sharp & Dohme (MSD)), which has 
generated the kind of excitement among treatment ex-
perts last seen with the onset of access to tenofovir or 
efavirenz. The drug is currently under consideration by 
the South African Medicines Control Council (MCC), and 
may be registered in the first half of 2009. Registered 
in late 2007 by the US Food and Drug Administration 
and the European Medicines Evaluation Agency on the 
back of trials showing high efficacy in patients with 
significant resistance from prior regimens, the drug has 
also been used successfully in drug-naïve patients, al-
though it is not currently registered for this. Data from 
the BENCHMRK trial recently showed that raltegravir 
was comparable to efavirenz in treatment-naïve patients 
after 96 weeks of treatment, with the advantage of a 
more favorable side-effect profile. Whether the benefit 
is sufficient to trigger a change in first-line prescribing is 
controversial, and guidelines still overwhelmingly favour 
efavirenz in drug-naïve patients.
Raltegravir is dosed twice daily, has no food restrictions, 
and appears to have relatively limited impact on the dif-
ferent cytochrome systems. The drug interaction with 
rifampicin is under investigation, and caution will be re-
quired during co-administration in tuberculosis patients 
until more data are received. There is some excitement 
among basic scientists that raltegravir may decrease the 
size of the ‘latent pool’ of HIV-infected cells, although 
the clinical importance of this seems questionable. 
However, the real excitement has been seen in those 
clinicians dealing with treatment-experienced patients, 
where the drug, when used with a new boosted PI, ap-
pears to control viraemia effectively and safely. Resist-
ance assays are being developed, and early evidence 
suggests that there is cross-resistance with other agents 
in the integrase class.
The major questions that hang over the raltegravir head 
are side-effects and cost. As with all drugs, side-effects 
are still unclear, and the usual regulatory agency care-
ful watching process is underway. It often takes several 
years for less common or long-term side-effects to be-
come apparent – witness the highly publicised if contro-
versial link between abacavir and myocardial infarction, 
only documented a decade after the drug became avail-
able. However, raltegravir has proved surprisingly popu-
lar, and a large number of patients have already been 
introduced to the drug in developed countries. Early 
safety data have been excellent, with no common seri-
ous side-effects. Initial therapy may be associated with 
mild gastrointestinal effects and dizziness, although 
the neuropsychiatric side-effects are significantly lower 
when compared with efavirenz in treatment-naïve pa-
tients. However, there have been several reports of in-
creased muscle toxicity and caution should be exercised 
in patients at risk of myopathy or rhabdomyloysis. The 
effect on lipid levels is minimal. By the time we have 
broad access to (or need) this agent in southern Africa, 
we should have a good idea of what sort of safety con-
cerns we need to be on the lookout for.
More immediately of concern is the cost. At the current 
$9 a day this is prohibitive, even for private care. Com-
petitor products are in development, with a drug called 
elvitegravir (from Gilead, of tenofovir fame), dosed daily 
and also with similar good preliminary data, which looks 
likely to be registered in the next few years but is unlikely 
to cost much less.
NEW NON-NUCLEOSIDE REVERSE tRANSCRIPtASE 
INHIBItORS (NNRtIs)
Efavirenz and nevirapine are the ‘non-nuke’ backbone of 
almost all new initiations in the developed and develop-
ing world. NNRTIs are convenient, relatively non-toxic, 
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and highly effective. Concerns surrounding drug inter-
actions, side-effects and efavirenz teratogencity are un-
likely to displace them from their role in first-line therapy 
for at least the next few years. The genetic barrier of this 
first-generation NNRTI is low, with resistance occurring 
rapidly and completely after a single mutation. Most vi-
rological failure patients therefore experience the loss of 
this class with their very first failure. It is also of concern 
that transmitted NNRTI resistance is well described and 
a growing problem in developed world settings.
With a lot less fanfare than the other new drugs, the 
new-generation NNRTIs have entered the fray. Etravirine 
(Intelence; Tibotec), a second-generation NNRTI, requires 
multiple mutations, and is effective in treating most pa-
tients who have failed efavirenz or nevirapine. Etravirine 
is interesting, as it was initially tested in conjunction 
with another experimental PI, a high-risk strategy for 
the pharmaceutical company. Toxicity profiles appear 
negligible so far, with rash and nausea the commonest 
symptoms.  
Etravirine seems to retain activity even in the presence 
of several mutations, behaving more like an NRTI than 
an NNRTI in this regard. However, specific etravirine-
associated mutations seem to occur more frequently 
in patients who have non-clade B virus and have been 
exposed to first-generation NNRTIs. Drug interactions 
appear to be significant and etravirine should not be 
administered in conjunction with boosted tipranavir, 
fosamprenavir or atazanavir and definitely not with un-
boosted PIs, thereby limiting its use in salvage regimens. 
It is not recommended for use alone with NRTIs in pa-
tients who are PI-naïve and have previously failed an 
NNRTI, owing to sub-optimal results in this group.
Complex to make, etravirine is likely to remain pro-
hibitively expensive for some time. The expense is com-
pounded by the fact that resistance testing and inter-
pretation is likely to be needed before using the drug, 
limiting its application in our setting. Interpretation of 
resistance is complex, with initial local data (personal 
communication, Professor Wendy Stevens, National 
Health Laboratory Services) suggesting that additional 
data will be needed before we can confidently predict 
responses in our region. Coupled with the fact that the 
southern African epidemic is predominantly clade C, and 
that first-generation NNRTIs are used extensively in first 
line with suboptimal virological monitoring, means that 
the jury will probably be out on this drug for some time.
CCR-5 INHIBItORS
The CCR-5 blockers (less commonly called chemokine 
antagonists) act on the major receptor that facilitates 
entry of HIV into the cell. Observations that mutations 
within the gene that codes for this receptor appear to 
profoundly modify the ability of the virus to enter, have 
led to the development of several therapeutic molecules, 
altered chemokines and monoclonal antibodies. Devel-
opment of these drugs was initially slowed after liver 
side-effects were observed, with one drug in the class, 
apliviroc (GSK), halted despite initial promising results. 
Pfizer’s maraviroc (the imaginatively named Selzentry 
in the USA; Celsentri elsewhere, licensed in 2007, and 
awaiting MCC registration in 2009) has been the first 
out of the starting blocks and has been approved in de-
veloped countries for treatment-experienced patients. 
Studies in these patients, done in record time to counter 
their competitors, have proven the drug performs well, 
and has a good short-term side-effect profile. The drug 
has been evaluated in head-to-head studies against efa-
virenz in naïve patients, but results have not been con-
vincing, and it seems unlikely at present that the drug 
can compete with the non-nukes in first line as yet.
The major problem with maraviroc is the necessity for 
tropism testing. CCR-5 is not the only entry point for 
HIV, and the ‘tropism’ or predisposition determination 
for these alternative entry points requires an expensive 
and complex test, which is not foolproof. A patient with 
a CXCR4 tropism predisposition is much less likely to re-
spond to the drug, so the test is essential. Resistance 
is usually characterised by a tropism switch to CXCR4, 
although this does not seem to have any direct immu-
nological consequence. The drug also has a significant 
impact on the cytochrome systems, much like the PIs, 
with drug interactions with other ARVs and opportunis-
tic infection medication, and requires dose modification 
in many common clinical circumstances.
An unexpected aside in one of the trials involving ma-
raviroc may have special implications for our region. 
The MERIT study compared maraviroc with efavirenz in 
antiretroviral-naïve subjects. There was little difference 
in terms of antiviral activity, but those who were giv-
en maraviroc developed only one incident TB infection 
while those in the efavirenz group had six. Scientists are 
excited, and are exploring the biological plausibility of 
Pfizer’s other blue pill: maraviroc, the first CCR-5 blocker, 
requires a tropism test before it can be used.
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this observation. Time will tell if this will strengthen the 
case for this drug, or possibly open up new TB preven-
tion options.
Pricing of maraviroc is likely to be an issue, as with all 
these new drugs, and an access price locally has yet to 
be determined. Currently the drug is available under a 
section 21 MCC approval for just under $1 000 month-
ly, which is prohibitive. Already one developed country 
health care system (the Scottish National Health Service) 
has declined the use of these agents due to the cost. 
The other potential CCR-5 blocker, vicriviroc, this time 
from Schering-Plough, has had a difficult time; an unex-
pected increase in malignancies, mainly lymphoma, was 
observed in one trial, and its predecessor, which is not 
structurally linked to vicriviroc, had unacceptable tox-
icity levels. This was counterintuitive, as patients with 
the previously described CCR-5 mutation are supposedly 
more protected against lymphoma (although the muta-
tion seems to be implicated in progression of breast can-
cer), so this finding created consternation. There is some 
fear that this may be a class effect, but the strange cor-
relation with cancer has not been seen with maraviroc. 
Subsequent statistical analysis suggested that the can-
cers were probably not linked. A theoretical link to West 
Nile virus suggested by another epidemiological study 
looking at CCR-5 mutations also stirred the pot, but no 
cases have yet been seen in treated patients. However, 
some clinicians are wary about this class of drug, which 
do not directly inhibit HIV replication, but rather play a 
more indirect effect on the immune system.
Entry inhibitors represent interesting candidates for 
pre-exposure prophylaxis from a biological plausibility 
standpoint (stopping the virus from penetrating at all, 
rather than arresting its development within the cell, as 
with current ART prophylaxis). If this concept turns out 
to be verified by trials, this use for this class of drug may 
turn out to be the most interesting yet.
PROtEASE INHIBItORS
For several years now, boosted PIs have formed the back-
bone of therapy after initial virological failure. Unpopular 
in first-line therapy because of their side-effect, meta-
bolic and cost profiles, PIs have established themselves 
as robust and highly effective alternative agents, and are 
recommended in all second-line therapies in the devel-
oping world, with lopinavir/ritonavir (Kaletra) being the 
most popular. An alternative and competitively priced PI, 
atazanavir, is available and better tolerated, but requires 
co-administration with separate ritonavir, due to pat-
ents being held by different pharmaceutical companies. 
There is a more appealing option with the registration of 
Alluvia, Kaeltra’s heat-stable formulation. With the rise 
of new agents, many of the older PIs, including nelfi-
navir, saquinavir and indinavir, have fallen steadily into 
disuse. Treatment expectations with the newer PIs are so 
high that international and local guidelines recommend 
a zero tolerance to detectable viral loads when these 
agents are used. Protease mutations appear more com-
plex than most other ART mutations, with a wide array 
of primary, secondary and background polymorphisms, 
some of which confer high-level resistance to the agent, 
and others that may confer hyper-susceptibility. The 
newer agents both select for mutations which require 
weighting systems in order to assess the effect of the 
multiple mutations they select for, making interpreta-
tion complex and requiring experience. The realisation 
that not all resistance is equal, that boosted PI resist-
ance may be more ‘forgiving’ of sub-optimal adherence, 
and that failure is rarely associated with significant PI 
mutations, has opened the way to effective third- and 
fourth-line regimens using these drugs, always in their 
boosted form.
New second-generation PIs darunavir (Prezista; Tibotec) 
and tipranavir (Aptivus; Boeringer-Ingelheim) both re-
quire boosting with ritonavir, but require a large number 
of mutations before they lose efficacy. The drugs carry 
the usual long list of drug interactions seen with PIs, 
making their administration complex.
Initial efficacy and toxicity data with boosted daruna-
vir (approved by the FDA in 2006), when compared with 
Kaletra, are very encouraging, and Tibotec is positioning 
the drug as a serious competitor to lopinavir/ritonavir 
after demonstrating good results in heavily treated pa-
tients and in those with moderate resistance, as well as 
in PI-naïve patients. Darunavir remains active in patients 
who are heavily treatment-experienced with demon-
strated resistance to all other PIs, including lopinavir/
ritonavir. In the TMC115 studies, 60% of subjects who 
had decreased susceptibility to tipranavir showed a de-
crease of more than 1 log in viral load after 24 weeks 
of treatment with darunavir, with over a third achieving 
complete suppression. This was clinically highly signifi-
cant in the era before the advent of integrase inhibi-
tors. There is some element of cross-resistance between 
darunavir and tipranavir, although half of isolates with 
darunavir resistance still demonstrated some suscepti-
bility to tipranavir. At this point, the actual sequencing 
of PIs – which should we use first so as to preserve the 
subsequent ones? – is a matter of much debate among 
clinicians.
Darunavir/ritonavir is dosed at 600/100 mg twice daily 
and must be taken with food. It is both a substrate and 
an inhibitor of CYP3A and therefore has similar drug in-
teractions to lopinavir/ritonavir. Among the severe side-
effects reported are skin rash (including Stevens-John-
son syndrome). Darunavir contains a sulfa-moiety and 
must be administered with caution in patients who are 
allergic to sulfa drugs.
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Interesting studies using darunavir as monotherapy af-
ter an initial intensification phase are also underway, de-
spite the disappointing results seen in the monotherapy 
studies with lopinavir/ritonavir. Other studies are looking 
at paediatric populations, and initial results have been 
very good in treatment-experienced children and ado-
lescents. 
Aspen, South Africa’s generic giant, has agreed to dis-
tribute darunavir (Prezista) in sub-Saharan Africa at a 
price of $3 a day, which remains expensive for the state 
sector but makes it an enticing option for managed care 
organisations.
Tipranavir is slightly older, registered in 2005 by the FDA 
for resistant patients and with a paediatric formulation 
registered in 2008. It is dosed twice daily with food, and 
requires a relatively high dose of ritonavir (200 mg twice 
daily) for effective boosting. Tipranavir and darunavir 
appear equally virologically effective. Drug side-effects 
are similar to other PIs in nature, with a curious report 
linking to the drug to intracranial haemorrhage still un-
der investigation. However, the drug has also performed 
very well in salvage regimens, firmly establishing itself as 
an option in treatment-experienced patients.
CONCLUSION
ART clinicians and their patients have an impressive new 
armamentarium looming. However, the cost and un-
known toxicities of these drugs mean that the longer we 
can preserve the first-line therapies we have, the better. 
For the developing world most, if not all, of these agents 
are currently unaffordable in the public and even the 
private sector. Toxicity data are often delayed, and will 
be widely publicised if significant, so we can afford to be 
cautious. For the small number of experienced patients 
who require these drugs, mechanisms exist for them to 
be accessed through the application (section 21) process 
set out by the Medicines Control Council.
First-line therapy, comprising two NRTIs and an NNRTI, 
is unlikely to change in the immediate future. In sec-
ond line, the choice of boosted PI seems fairly evenly 
matched, although preliminary data suggest that the 
well-established lopinavir/ritonavir has some less toxic 
competitors, mainly from new PIs but potentially even 
from the other newcomers. While raltegravir looks in-
creasingly attractive as a second-line alternative to 
existing choices, as does etravirine, both remain unaf-
fordable at this time. A very rapid change from first-line 
regimens that include first-generation NNRTIs appears 
to be the only way to preserve etravirine; close virologi-
cal monitoring may be the answer to the relatively low 
genetic barrier of raltegravir. Use of the CCR-5 inhibi-
tors is limited by their reliance on extremely expensive 
tropism assays and they will have little to no immediate 
place in the developing world unless both their pricing 
structure and their tropism assay reliance are resolved.
Debate rests as to how a third-line regimen should be 
structured, but it is likely to be expensive, if not par-
ticularly toxic, and will still require significant expertise 
on the part of clinicians. Optimal use of these agents 
would depend on expensive genotyping assays, beyond 
the reach of many public sector programmes in southern 
Africa.
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